WebRiclassificazione del medicinale per uso umano «Tepmetko», ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 96/2024). (23A01094) (GU n.48 del 25-2-2024) IL DIRIGENTE del Settore HTA ed economia del farmaco Visto l'art. 48 del decreto-legge 30 settembre 2003, n. 269, Web28 feb 2024 · Tepmetko è un farmaco a base del principio attivo Tepotinib, appartenente alla categoria degli Antineoplastici e nello specifico Altri inibitori proteinchinasi. E' commercializzato in Italia dall'azienda Merck Serono S.p.A..
Tepmetko European Medicines Agency
WebONC includes a Patient Assistance Program (PAP) that provides TEPMETKO ® (tepotinib) at no charge to patients who meet certain insurance (i.e., uninsured), income, and residency eligibility criteria. To determine patient eligibility, providers should complete and fax the ONC Enrollment Form prior to treatment to 1-844-501-0062 Web5 mag 2024 · Tepmetko is a cancer medicine that is used to treat adults with non-small cell lung cancer (NSCLC) when the cancer is advanced and its cells have particular genetic … terbitan pusat teknologi penerbangan lapan
TEPMETKO® Safety Information - Metastatic NSCLC with METex14
WebTEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 … Web20 apr 2024 · Health Canada granted marketing authorization for Jardiance (empagliflozin) 10 mg in chronic heart failure as adjunct to standard of care therapy, announced Boehringer Ingelheim and Eli Lilly. The treatment is the first to receive approval for patients with chronic heart failure regardless of ejection fraction, which means the approval covers both … Web28 feb 2024 · Tepmetko - compresse rivestite (Tepotinib):Antineoplastici e' un farmaco a base del principio attivo Tepotinib, appartenente alla categoria degli Antineoplastici e … terbitan tidak berkala